Compare KRUS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | REPL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.2M | 454.6M |
| IPO Year | 2019 | 2018 |
| Metric | KRUS | REPL |
|---|---|---|
| Price | $48.20 | $13.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $81.11 | $5.67 |
| AVG Volume (30 Days) | 222.8K | ★ 6.9M |
| Earning Date | 04-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | N/A |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $42.62 | $1.50 |
| 52 Week High | $87.99 | $13.90 |
| Indicator | KRUS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 62.64 |
| Support Level | $47.15 | $6.80 |
| Resistance Level | $50.25 | N/A |
| Average True Range (ATR) | 1.92 | 1.55 |
| MACD | 0.43 | 0.41 |
| Stochastic Oscillator | 74.48 | 95.72 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.